AVNS — Avanos Medical Income Statement
0.000.00%
Last trade - 00:00
- $1.11bn
- $1.19bn
- $673.30m
- 83
- 55
- 95
- 91
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 698 | 715 | 745 | 684 | 673 |
Cost of Revenue | |||||
Gross Profit | 402 | 373 | 364 | 394 | 380 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 753 | 761 | 736 | 650 | 669 |
Operating Profit | -55.7 | -46.1 | 8.9 | 34.4 | 4.2 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -64 | -60.5 | 5.8 | 26.7 | -7.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -45.9 | -27.2 | 5.2 | 21.5 | -9.9 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -45.9 | -27.2 | 5.2 | 50.5 | -61.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -45.9 | -27.2 | 5.2 | 50.5 | -61.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.81 | 0.69 | 1.05 | 0.713 | 0.502 |